Medical Journal of the Islamic Republic Of Iran
مجله پزشکی جمهوری اسلامی ایران
Med J Islam Repub Iran
Medical Sciences
http://mjiri.iums.ac.ir
2
journal2
1016-1430
2251-6840
8
10.18869/mjiri
14
8888
13
en
jalali
1395
10
1
gregorian
2017
1
1
31
1
online
1
fulltext
en
Cost-effectiveness of eplerenone in treatment of cardio-vasculardiseases: a systematic review
Health Management and Economics
Health Management and Economics
Original Research
Original Research
<p><strong>Introduction:</strong> In recent years, a few studies have been conducted in the area of the cost-effectiveness of the Eplerenone; it's notable that coherent and clear evidence are not available. Therefore, this study aimed to systematically review studies of cost-effectiveness of Eplerenone in the treatment of cardio-vascular patients.</p>
<p><strong>Methods:</strong> This systematic review study was conducted in 2016. The required information were collected by using key Mesh words from databases such as: Google scholar, PubMed, Science Direct, MagIran, SID, Scopus and hand searching journals and selected articles references. The Quality of selected articles was assessed by the Drummond's check-list.</p>
<p><strong>Results:</strong> Nine articles were included from 296 articles found in literature review. Studies have been conducted in 8 countries (America, Britain, Australia, Switzerland, France, Spain, the Netherlands and Canada). In general, the cost-effectiveness of Eplerenone was investigated on 31757 in treating cardio-vascular patients. Average of quality-adjusted life years (QALY) in studies with non-modeling was equal to 0.0908 in terms of Framingham approach, 0.0595 in terms of Saskatchewan approach and 0.1309 in terms of Worcester approach. In general, the overall average cost of treating cardiovascular patients with Eplerenone was equal to $6694 of America in one year. The cost per additional (QALY) was estimated to be $ 9478 of America. Incremental cost-effectiveness ratio was high in the United States compared to European countries. The Average quality of articles was estimated about 7.4 from 10.</p>
<p><strong>Conclusion:</strong> Based on the results of the studies reviewed in this study, it seems that Eplerenone has acceptable cost-effectiveness compared with current treatments, placebo and similar drugs.</p>
<p></p>
Cost-effectiveness, Cardiovascular disease, Eplerenone, Systematic review
13
22
http://mjiri.iums.ac.ir/browse.php?a_code=A-10-3040-1&slc_lang=en&sid=1
Hossein
Mobaraki
hmobaraki43@yahoo.com
200319475328460029882
200319475328460029882
No
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
Saber
Azami-Aghdash
saberazami@yahoo.com
200319475328460029883
200319475328460029883
No
Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Ali
Sarabi Asiabar
sarabi.a@iums.ac.ir
200319475328460029884
200319475328460029884
No
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Aziz
Rezapour
rezapoor_a57@yahoo.com
200319475328460029885
200319475328460029885
No
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein
Kafaei Mehr
m.h_kafa@yahoo.com
200319475328460029886
200319475328460029886
Yes
Health Management and Economics Research Center, Iran University of Medical Sci-ences, Tehran, Iran.
Saeed
Emamgolizadeh
m.h_kafa@yahoo.com
200319475328460029887
200319475328460029887
No
shomal university, Amol, Iran